US FDA extends approval of Epclusa (sofosbuvir and velpatasvir) to include treatment of children with hepatitis C virus (HCV)

In the US, this product is now licensed for use in the treatment of HCV in children ages 6 years and older or weighing at least 17 kg with any of the six HCV genotypes. In the UK, it remains licensed only for the treatment of HCV in adults.